Nykode Therapeutics ASA Asset Resilience Ratio
Nykode Therapeutics ASA asset resilience ratio. Nykode Therapeutics ASA (NYKD) has an Asset Resilience Ratio of 60.32% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Nykode Therapeutics ASA to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Nykode Therapeutics ASA (2016–2025)
Asset resilience ratio of Nykode Therapeutics ASA from 2016 to 2025. This chart shows how Nykode Therapeutics ASA's Asset Resilience Ratio has changed over time. Read NYKD current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Nykode Therapeutics ASA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see NYKD current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr60.29 Million | 60.32% |
| Short-term Investments | Nkr0.00 | 0% |
| Total Liquid Assets | Nkr60.29 Million | 60.32% |
Asset Resilience Insights
- Very High Liquidity: Nykode Therapeutics ASA maintains exceptional liquid asset reserves at 60.32% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Nykode Therapeutics ASA Industry Peers by Asset Resilience Ratio
Compare Nykode Therapeutics ASA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Immunovant Inc
NASDAQ:IMVT |
Biotechnology | 98.50% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
Nykode Therapeutics ASA Asset Resilience Ratio by Year (2016–2025)
Nykode Therapeutics ASA asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Nykode Therapeutics ASA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 60.32% | Nkr60.29 Million ≈ $6.34 Million |
Nkr99.95 Million ≈ $10.52 Million |
-14.49pp |
| 2024-12-31 | 74.81% | Nkr114.82 Million ≈ $12.08 Million |
Nkr153.48 Million ≈ $16.15 Million |
-2.98pp |
| 2023-12-31 | 77.79% | Nkr161.95 Million ≈ $17.04 Million |
Nkr208.19 Million ≈ $21.91 Million |
-15.15pp |
| 2022-12-31 | 92.94% | Nkr205.84 Million ≈ $21.66 Million |
Nkr221.48 Million ≈ $23.31 Million |
+88.36pp |
| 2021-12-31 | 4.58% | Nkr12.17 Million ≈ $1.28 Million |
Nkr265.56 Million ≈ $27.94 Million |
-6.26pp |
| 2020-12-31 | 10.84% | Nkr24.94 Million ≈ $2.62 Million |
Nkr230.03 Million ≈ $24.21 Million |
-54.10pp |
| 2019-12-31 | 64.94% | Nkr190.33 Million ≈ $20.03 Million |
Nkr293.08 Million ≈ $30.84 Million |
-28.71pp |
| 2018-12-31 | 93.65% | Nkr143.60 Million ≈ $15.11 Million |
Nkr153.34 Million ≈ $16.14 Million |
-2.58pp |
| 2017-12-31 | 96.23% | Nkr206.37 Million ≈ $21.72 Million |
Nkr214.47 Million ≈ $22.57 Million |
+86.31pp |
| 2016-12-31 | 9.92% | Nkr2.47 Million ≈ $260.24K |
Nkr24.93 Million ≈ $2.62 Million |
-- |
About Nykode Therapeutics ASA
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication… Read more